Efficacy of Antihistamine Dosing-up and add-on Treatment With H2-receptor Antagonist
NCT ID: NCT03293225
Last Updated: 2019-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
110 participants
OBSERVATIONAL
2017-08-24
2019-05-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria
NCT06819774
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
NCT03436797
Detection of Viral Particels in Urticaria Patients
NCT03151902
To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients
NCT03655210
A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
NCT05335499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* After the researcher confirms the selection / exclusion criteria on the baseline, the UAS, K-UCT, and CU-QoL are created and randomized from the subject.
* Receive UAS, K-UCT, and CU-QoL from the subject during the last visit to assess safety
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
add H2RA
Add antihistamines to standard drug therapy
No interventions assigned to this group
change ns-H1RA
Change to ns-H1RA in standard medication
No interventions assigned to this group
ns-H1RA(3-4 tabs)
Standard treatment with ns-H1RA 4X dose
No interventions assigned to this group
ns-H1RA(3-4kinds)
Use of NS 4 kinds for standard treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of chronic urticaria due to wheal reaction, itching, angioedema over 6 weeks
* Antihistamine 2 or 2 kinds of treatment for more than 2 weeks even if the symptoms are not controlled
* Those who do not have other chronic skin diseases
Exclusion Criteria
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ajou University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ye Youngmin
professor, Department alleric internal medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Youngmin Ye, Dr
Role: STUDY_DIRECTOR
Ajou University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ajou University Medical Hospital
Suwon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AJIRB-MED-OBS-17-173
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.